In vitro anti-leukemic effect of Wharton's jelly derived mesenchymal stem cells

Area of Science:

• Cell Biology
• Cancer Research
• Stem Cell Therapy

Background:

• Mesenchymal stem cells (MSCs) possess self-renewal and multi-potent capabilities.
• MSCs are investigated for their potential anti-cancer effects, making them candidates for cell-based therapies.
• Wharton's Jelly-derived MSCs (WJ-MSCs) were the focus for evaluating anti-leukemic properties.

Purpose of the Study:

• To assess the in vitro anti-leukemic effects of WJ-MSCs.
• To determine the impact of WJ-MSCs on K562 and HL-60 leukemic cell lines.
• To investigate the mechanism of WJ-MSC anti-leukemic action, specifically apoptosis induction.

Main Methods:

• WJ-MSCs were isolated from human umbilical cord and characterized via flow cytometry.
• Direct co-culture of WJ-MSCs with K562 and HL-60 cells at a 1:5 ratio was performed.
• Apoptosis was quantified using Annexin V/PI staining, with HUVEC cells serving as a non-cancerous control.

Main Results:

• Direct co-culture of WJ-MSCs induced significant apoptosis in K562 and HL-60 leukemic cells.
• Elevated apoptosis rates were observed in leukemic cell lines treated with WJ-MSCs.
• Minimal apoptosis was detected in the non-cancerous HUVEC cell line, indicating specificity.

Conclusions:

• WJ-MSCs demonstrated a strong inhibitory effect on the viability of HL-60 and K562 cells.
• The study confirmed WJ-MSC-mediated induction of apoptosis in leukemia cell lines in vitro.
• Results suggest WJ-MSCs hold promise for future clinical applications in cancer therapy by inhibiting tumor growth.